Key TakeawaysIDEAYA Biosciences reported positive results from a Phase 2 trial of its experimental drug to treat certain bladder and small-cell lung cancers on Monday, and shares soared in intraday trading.The once-a-day tablet IDE397 helped patients with MTAP-deletion solid cancers.The company noted there are no Food and Drug Administration (FDA)-approved drugs for those who have MTAP-deletion solid tumors. Shares of IDEAYA Biosciences (IDYA) took off in intraday trading Monday after the biotech announced ...